With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

GSK Pharmaceuticals reports a temporary production disruption due to a fire at one of its contract manufacturing facilities; ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

LONDEN - GSK plc (LSE/NYSE: GSK) heeft vandaag samen met iTeos Therapeutics, Inc. aangekondigd dat ze hun gezamenlijke ontwikkelingsprogramma voor belrestotug, een experimenteel anti-TIGIT-monoclonaal ...

GSK plc (LSE/NYSE: GSK) heeft de overname aangekondigd van efimosfermin alfa, een veelbelovende behandeling voor steatotische leverziekte (SLD), van Boston Pharmaceuticals. De deal, met een directe ...

GSK PLC GSK shares rose 2.35% to £13.95 Friday, on what proved to be an all-around positive trading session for the stock ...

The drugmaking giant plans to pay $1.2billion upfront to acquire Efirmosfermin from Boston Pharmaceuticals, followed by ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...